Select Equity Group L.P. Buys Shares of 10,092 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Select Equity Group L.P. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,092 shares of the medical equipment provider’s stock, valued at approximately $903,000.

Several other hedge funds also recently modified their holdings of the business. Janus Henderson Group PLC lifted its stake in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after buying an additional 435,445 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Lantheus during the 4th quarter worth about $36,183,000. Finally, Swedbank AB increased its holdings in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LNTH shares. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $132.67.

Lantheus Trading Up 1.8%

LNTH opened at $81.24 on Friday. The business has a 50 day moving average of $97.11 and a 200-day moving average of $93.20. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a 1-year low of $75.00 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus’s revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the company earned $1.69 earnings per share. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.